Abstract
This study was performed to evaluate the clinical value of somatostatin receptor scintigraphy (SRS) in the diagnostic management of patients having recurrent medullary thyroid cancer (MTC). In 22 patients with recurrent MTC after primary surgical intervention, 33 SRS were performed. Planar imaging was carried after i.v. administration of 180 MBq of [In]-DTPA-D-Phe-octreotide (Octreoscan®), SPET of the neck and thoracic regions. The scintigraphical results were compared with the tumor markers human calcitonin (hCT), CEA, other imaging methods, histological findings, and clinical follow-up. In 36% (8/22) of the cases, SRS was concordant to the defined gold standard in the detection or exclusion of tumor tissue. If patients with liver metastases are excluded, SRS was positive in hCT levels >6.4 ng/ml and in hCT/CEA ratios >0.38. SRS can only be recommended to clear up equivocal findings especially in patients having sufficiently elevated titers of hCT levels and hCT/CEA ratios.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
